Binzen, Germany

Achim Guettner

USPTO Granted Patents = 3 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2017-2022

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Achim Guettner: Innovator in Psoriasis Treatment

Introduction

Achim Guettner is a notable inventor based in Binzen, Germany. He has made significant contributions to the field of dermatology, particularly in the treatment of psoriasis. With a total of three patents to his name, Guettner's work focuses on innovative methods that utilize IL-17 antagonists.

Latest Patents

Guettner's latest patents include groundbreaking methods for treating psoriasis using IL-17 antagonists. One of his patents discloses novel regimens that employ a therapeutically effective amount of an IL-17 antagonist, such as an IL-17 binding molecule or an IL-17 antibody, including the secukinumab antibody. Another patent similarly outlines methods of treating psoriasis using IL-17 antibodies, emphasizing the therapeutic potential of these innovative treatments.

Career Highlights

Achim Guettner has established a successful career in the pharmaceutical industry, working with Novartis AG. His expertise in developing treatments for psoriasis has positioned him as a key figure in the field. His contributions have the potential to improve the quality of life for many individuals suffering from this chronic skin condition.

Collaborations

Guettner has collaborated with notable colleagues, including Matthias Machacek and Charis Papavassilis. These partnerships have likely enhanced the development and refinement of his innovative treatment methods.

Conclusion

Achim Guettner's work in psoriasis treatment exemplifies the impact of innovation in medicine. His patents reflect a commitment to advancing therapeutic options for patients, showcasing the importance of research and collaboration in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…